Partnership Helsinn Healthcare & InVirtuoLabs sign a Strategic Collaboration in AI-Driven Drug Discovery
Life-cycle development Helsinn announces European Commission approval of AKYNZEO® Oral Suspension
Partnership Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
Partnership Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria
Corporate Helsinn announces new Executive Leadership Team as it celebrates 50 years
Life-cycle development Results from the MyRisk clinical trial, accepted for publication in the Annals of Oncology, will be presented today at ESMO 2025 as an oral presentation
Life-cycle development Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
Life-cycle development Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
Corporate Helsinn closes financing agreement with BancaStato to support business objectives and growth
Life-cycle development Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
